Eric Estrin

Eric received a BS in Biochemistry from UT-Austin before getting his PhD at UC-Berkeley. At Berkeley he trained in Andreas Martin's lab, where he enabled the discovery of the subunit architecture and assembly of the 26S Proteasome by developing a novel heterologous production system. Since then, he has engineered proteins for therapeutic applications at NGM Bio, Celgene, and most recently Spotlight Therapeutics where he developed antibody-Cas nuclease bioconjugates for selective in vivo gene editing.